Eolas Therapeutics

Executive Summary

Eolas Therapeutics is a private biotechnology company founded in 2018 and headquartered in Dublin, Ohio, USA. The company is dedicated to developing innovative therapies for addiction and other neurological disorders, addressing significant unmet medical needs. By leveraging a patient-centric approach and novel science, Eolas aims to improve the quality of life for individuals suffering from conditions such as substance use disorders and related neurological indications. Despite being in an early stage, the company's focus on addiction—a area with high societal burden and limited effective treatments—positions it as a potentially impactful player in the neuroscience and oncology adjacent space. However, as a private entity with limited public information, the company's progress and pipeline specifics remain largely undisclosed, leading to moderate conviction in its near-term prospects.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Addiction Therapy40% success
• Q4 2026Initiation of Phase 1 Clinical Trial for Neurological Disorder Program30% success
• Q4 2026Presentation of Preclinical Data at Major Neuroscience Conference50% success